{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05625490",
            "orgStudyIdInfo": {
                "id": "202107042-2"
            },
            "secondaryIdInfos": [
                {
                    "id": "R01HL142297",
                    "type": "NIH",
                    "link": "https://reporter.nih.gov/quickSearch/R01HL142297"
                }
            ],
            "organization": {
                "fullName": "Washington University School of Medicine",
                "class": "OTHER"
            },
            "briefTitle": "Myocardial Perfusion Imaging Galmydar Rest/Stress",
            "officialTitle": "Development and Translation of Generator-Produced PET Tracer for Myocardial Perfusion Imaging",
            "therapeuticArea": [
                "Cardiovascular"
            ],
            "study": "myocardial-perfusion-imaging-galmydar-rest-stress"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-04",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2022-11-11",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2025-04-01",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2025-04-01",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2022-11-13",
            "studyFirstSubmitQcDate": "2022-11-20",
            "studyFirstPostDateStruct": {
                "date": "2022-11-23",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-04-25",
            "lastUpdatePostDateStruct": {
                "date": "2024-04-26",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "PRINCIPAL_INVESTIGATOR",
                "investigatorFullName": "Pamela Woodard, MD",
                "investigatorTitle": "H M Wilson Professor of Radiology",
                "investigatorAffiliation": "Washington University School of Medicine"
            },
            "leadSponsor": {
                "name": "Washington University School of Medicine",
                "class": "OTHER"
            },
            "collaborators": [
                {
                    "name": "National Institutes of Health (NIH)",
                    "class": "NIH"
                },
                {
                    "name": "National Heart, Lung, and Blood Institute (NHLBI)",
                    "class": "NIH"
                }
            ]
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "A single center, phase 0/1 clinical imaging study designed to assess the role of \\[68Ga\\]Galmydar PET/CT imaging in human subjects.",
            "detailedDescription": "The primary objective of the proposed study is to evaluate the potential of \\[68Ga\\]Galmydar PET/CT MPI for the noninvasive detection of coronary artery disease. The study will evaluate \\[68Ga\\]Galmydar PET/CT MPI in comparison to \\[13N\\]ammonia PET/CT MPI to semi-quantitatively assess regional myocardial perfusion and quantitatively assess myocardial blood flow (MBF) in patients with suspected or known coronary artery disease (CAD) undergoing clinical SPECT MPI. In addition, perfusion and MBF findings with \\[68Ga\\]Galmydar will be compared to the results of coronary morphology or stenosis severity in those patients undergoing invasive coronary angiography (ICA) based on abnormal SPECT MPI. The performance of rest/stress \\[68Ga\\]Galmydar PET/CT in comparison to \\[13N\\]ammonia PET/CT in normal subjects without cardiovascular disease will be performed as a control. The primary objective of the proposed study is to evaluate the potential of \\[68Ga\\]Galmydar PET/CT MPI for the noninvasive detection of coronary artery disease. The study will evaluate \\[68Ga\\]Galmydar PET/CT MPI in comparison to \\[13N\\]ammonia PET/CT MPI in the same subjects to semi quantitatively assess regional myocardial perfusion and quantitatively assess myocardial blood flow (MBF) in patients with suspected or known coronary artery disease (CAD) undergoing clinical SPECT MPI. In addition, perfusion and MBF findings with \\[68Ga\\]Galmydar will be compared to the results of coronary morphology or stenosis severity in those patients undergoing invasive coronary angiography (ICA) based on abnormal SPECT MPI. The performance of rest/stress \\[68Ga\\]Galmydar PET/CT in comparison to \\[13N\\]ammonia PET/CT in normal subjects without cardiovascular disease will be performed as a control. Vital signs, serum chemistries, and serum blood counts will also be obtained."
        },
        "conditionsModule": {
            "conditions": [
                "Coronary Artery Disease"
            ],
            "keywords": [
                "Myocardial Perfusion imaging",
                "Pharmacological Stress",
                "Positron Emission Tomography",
                "Myocardial Blood Flow"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "EARLY_PHASE1"
            ],
            "designInfo": {
                "allocation": "NON_RANDOMIZED",
                "interventionModel": "PARALLEL",
                "interventionModelDescription": "Patients with known or suspected disease and normal controls (no known disease) will both undergo \\[68Ga\\]Galmydar PET/CT MPI and \\[13N\\]ammonia PET/CT MPI",
                "primaryPurpose": "DIAGNOSTIC",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 30,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Rest/ Stress imaging day 1",
                    "type": "EXPERIMENTAL",
                    "description": "Participants will receive two \\[68Ga\\]Galmydar intravenous administrations, 4 mCi during rest and 8 mCi during stress for the PET MPI performed on Imaging Day-1.",
                    "interventionNames": [
                        "Drug: Ga-68 Galmydar"
                    ]
                },
                {
                    "label": "rest/ stress imaging day 2",
                    "type": "EXPERIMENTAL",
                    "description": "On Imaging Day-2, participants will receive two single administrations each of 10 mCi of 13N-Ammonia during the rest and stress PET MPI.",
                    "interventionNames": [
                        "Drug: 13N-ammonia"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Ga-68 Galmydar",
                    "description": "Two intravenous injection of the PET radiotracer 68Ga-Galmydar.",
                    "armGroupLabels": [
                        "Rest/ Stress imaging day 1"
                    ],
                    "otherNames": [
                        "IND 157468"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "13N-ammonia",
                    "description": "Two intravenous Injection of PET radiotracer 13N-Ammonia.",
                    "armGroupLabels": [
                        "rest/ stress imaging day 2"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Semiquantitative assessment of 68Ga-Galmydar PET/CT uptake",
                    "description": "Assessment of regional (17segment) myocardial uptake on 5-point scale (0 = normal; 4 = absent tracer uptake) per independent blind readout by 3 expert cardiac PET physicians.",
                    "timeFrame": "Comparison to regional uptake on 13N-ammonia PET/CT performed 3-30 days after the 68Ga-Galmydar PET/CT"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Assessment of myocardial blood flow on 68Ga-Galmydar PET/CT",
                    "description": "Assessment of regional (17segment) myocardial blood flow (MBF) at stress and rest perfusion on 68Ga-Galmydar PET/CT.",
                    "timeFrame": "Comparison to regional MBF on 13N-ammonia PET/CT performed 3-30 days after the 68Ga-Galmydar PET/CT"
                },
                {
                    "measure": "Change in systolic or diastolic blood pressure.",
                    "description": "A 20 mmHg change from baseline in either systolic or diastolic blood pressure.",
                    "timeFrame": "6 hours from 68Ga-Galmydar injection"
                },
                {
                    "measure": "Change in heart rate.",
                    "description": "A 20 BPM change in heart rate from baseline.",
                    "timeFrame": "6 hours from 68Ga-Galmydar injection"
                },
                {
                    "measure": "Clinically significant change in respiratory rate.",
                    "description": "A respiratory rate of \\< 12 or \\> 20 breaths/min.",
                    "timeFrame": "6 hours from 68Ga-Galmydar injection"
                },
                {
                    "measure": "Clinically significant elevation in oral temperature",
                    "description": "Oral temperature of \\>100 degrees F.",
                    "timeFrame": "6 hours from 68Ga-Galmydar injection"
                },
                {
                    "measure": "Number of patients with new AV Block",
                    "description": "A change in EKG showing new AV Block (Type 1 or Type 2), Mobitz 2:1, or QTc \u2265 500ms).",
                    "timeFrame": "6 hours from 68Ga-Galmydar injection"
                },
                {
                    "measure": "Number of patients with new bradycardia",
                    "description": "New heart rate \\< 40 BPM on EKG.",
                    "timeFrame": "6 hours from 68Ga-Galmydar injection"
                },
                {
                    "measure": "Clinically significant change in serum chemistries: sodium, potassium, chloride, CO2",
                    "description": "Serum chemistries (sodium, potassium, chloride, CO2) measured in mmol/L. Values outside of laboratory range in comparison to baseline or \\>20% difference from baseline values.",
                    "timeFrame": "6 hours from 68Ga-Galmydar injection"
                },
                {
                    "measure": "Clinically significant change in serum chemistries: glucose, calcium creatinine, BUN, total bilirubin",
                    "description": "Serum chemistries (glucose, calcium creatinine, BUN, total bilirubin), measured in mg/dL. Values outside of laboratory range in comparison to baseline or \\>20% difference from baseline values.",
                    "timeFrame": "6 hours from 68Ga-Galmydar injection"
                },
                {
                    "measure": "Clinically significant change in serum chemistries: total protein, albumin.",
                    "description": "Serum chemistries (total protein, albumin), measured in g/dL. Values outside of laboratory range in comparison to baseline or \\>20% difference from baseline values.",
                    "timeFrame": "6 hours from 68Ga-Galmydar injection"
                },
                {
                    "measure": "Clinically significant change in serum chemistries: alkaline phosphatase, ALT, AST",
                    "description": "Serum chemistries (alkaline phosphatase), measured in U/L. Values outside of laboratory range in comparison to baseline or \\>20% difference from baseline values.",
                    "timeFrame": "6 hours from 68Ga-Galmydar injection"
                },
                {
                    "measure": "Clinically significant change in white blood cell count (WBC)",
                    "description": "White blood cell count measured in WBC/mm3 blood. Values outside of laboratory range in comparison to baseline or \\>20% difference from baseline values.",
                    "timeFrame": "6 hours from 68Ga-Galmydar injection"
                },
                {
                    "measure": "Clinically significant change in hemoglobin (Hgb)",
                    "description": "Hgb measured in g/dL. Values outside of laboratory range in comparison to baseline or \\>20% difference from baseline values.",
                    "timeFrame": "6 hours from 68Ga-Galmydar injection"
                },
                {
                    "measure": "Clinically significant change in hematocrit (Hct)",
                    "description": "Hct measured in %. Values outside of laboratory range in comparison to baseline or \\>20% difference from baseline values.",
                    "timeFrame": "6 hours from 68Ga-Galmydar injection"
                },
                {
                    "measure": "Clinically significant change in platelets",
                    "description": "Platelets measured in platelets/mm3 blood. Values outside of laboratory range in comparison to baseline or \\>20% difference from baseline values.",
                    "timeFrame": "6 hours from 68Ga-Galmydar injection"
                },
                {
                    "measure": "Clinically significant change in red blood cell count (RBC)",
                    "description": "RBC measured in million/mm3. Values outside of laboratory range in comparison to baseline or \\>20% difference from baseline values.",
                    "timeFrame": "6 hours from 68Ga-Galmydar injection"
                },
                {
                    "measure": "Clinically significant change in mean corpuscular volume (MCV)",
                    "description": "MCV measured in \u00b5m3. Values outside of laboratory range in comparison to baseline or \\>20% difference from baseline values.",
                    "timeFrame": "6 hours from 68Ga-Galmydar injection"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Male and female, 18-99 years of age and any race;\n* Have had a prior clinical SPECT MPI positive for ischemia in two myocardial segments and referred for invasive coronary angiography (ICA) or have had a prior clinical SPECT MPI negative for ischemia;\n\nExclusion Criteria:\n\n* Inability to receive and sign informed consent;\n* Percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) within 6-months prior to SPECT or in the intervening days between SPECT and PET examination;\n* Participants who have received chemotherapeutic agents within 6 months of enrollment;\n* Heart failure (left ventricular ejection fraction \u2264 35%);\n* Known non-ischemic cardiomyopathy;\n* Inability to undergo pharmacologic stress testing with regadenoson (Lexiscan). Contraindications include:\n\n  * Symptomatic bradycardia or second to third degree atrioventricular (AV) block;\n  * Pre-existing obstructive lung disease with active wheezing, i.e., COPD, asthma with active wheezing that precludes the safe administration of the pharmacological stress agent according to the approved label;\n  * Uncontrolled and severe hypertension (e.g. systolic blood pressure \\>200 mmHg, diastolic blood pressure \\>110 mmHg);\n  * Baseline hypotension (e.g. systolic blood pressure \\< 90 mmHg, diastolic blood pressure \\<50 mmHg);\n* Women who are pregnant or breastfeeding;\n* Severe claustrophobia;\n* Weight \u2265 500 lbs (weight limit of PET/CT table)",
            "healthyVolunteers": true,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "maximumAge": "99 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Dakkota M Thies",
                    "role": "CONTACT",
                    "phone": "314-747-3839",
                    "email": "d.thies@wustl.edu"
                },
                {
                    "name": "Kitty D Harrison, R.N",
                    "role": "CONTACT",
                    "phone": "314-747-0183",
                    "email": "kittydharrison@wustl.edu"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Pamela K Woodard, M.D",
                    "affiliation": "Washington University School of Medicine",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "Washington University School of Medicine",
                    "status": "RECRUITING",
                    "city": "Saint Louis",
                    "state": "Missouri",
                    "zip": "63110",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Dakkota m Thies",
                            "role": "CONTACT",
                            "phone": "314-747-3839",
                            "email": "d.thies@wustl.edu"
                        },
                        {
                            "name": "Kitty D Harrison, R.N",
                            "role": "CONTACT",
                            "phone": "314-747-0183",
                            "email": "kittydharrison@wustl.edu"
                        },
                        {
                            "name": "Pamela K Woodard, M.D",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        },
                        {
                            "name": "Thomas Schindler, MD, PHD",
                            "role": "SUB_INVESTIGATOR"
                        },
                        {
                            "name": "Vijay Sharma, PHD",
                            "role": "SUB_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 38.62727,
                        "lon": -90.19789
                    }
                }
            ]
        },
        "referencesModule": {
            "references": [
                {
                    "pmid": "29454148",
                    "type": "BACKGROUND",
                    "citation": "Sivapackiam J, Laforest R, Sharma V. 68Ga[Ga]-Galmydar: Biodistribution and radiation dosimetry studies in rodents. Nucl Med Biol. 2018 Apr;59:29-35. doi: 10.1016/j.nucmedbio.2017.11.008. Epub 2017 Dec 1."
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000003324",
                    "term": "Coronary Artery Disease"
                }
            ],
            "ancestors": [
                {
                    "id": "D000003327",
                    "term": "Coronary Disease"
                },
                {
                    "id": "D000017202",
                    "term": "Myocardial Ischemia"
                },
                {
                    "id": "D000006331",
                    "term": "Heart Diseases"
                },
                {
                    "id": "D000002318",
                    "term": "Cardiovascular Diseases"
                },
                {
                    "id": "D000001161",
                    "term": "Arteriosclerosis"
                },
                {
                    "id": "D000001157",
                    "term": "Arterial Occlusive Diseases"
                },
                {
                    "id": "D000014652",
                    "term": "Vascular Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M6546",
                    "name": "Coronary Artery Disease",
                    "asFound": "Coronary Artery Disease",
                    "relevance": "HIGH"
                },
                {
                    "id": "M19506",
                    "name": "Myocardial Ischemia",
                    "relevance": "LOW"
                },
                {
                    "id": "M6549",
                    "name": "Coronary Disease",
                    "relevance": "LOW"
                },
                {
                    "id": "M10543",
                    "name": "Ischemia",
                    "relevance": "LOW"
                },
                {
                    "id": "M9419",
                    "name": "Heart Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M4469",
                    "name": "Arteriosclerosis",
                    "relevance": "LOW"
                },
                {
                    "id": "M4465",
                    "name": "Arterial Occlusive Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M17400",
                    "name": "Vascular Diseases",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC14",
                    "name": "Heart and Blood Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                }
            ]
        }
    },
    "hasResults": false
}